Seagen Inc. Files SEC Form 4 Disclosure
A U.S. Securities and Exchange Commission (SEC) filing by Seagen Inc. on March 3, 2023, revealed a notable disclosure. The SIC code for this company is 2836, Biological Products, specifically excluding Diagnostic Substances. As per the SEC filing, Seagen Inc.'s contact information is 21823 30TH DRIVE SE, SUITE, BOTHELL WA 98021, 4255274000. This disclosure is part of Seagen Inc.'s regulatory obligations under the '34 Act, requiring directors, officers, and owners of more than ten percent of a class of equity securities to submit statements of ownership regarding such security.
Key Takeaways:
- Seagen Inc. filed Form 4 with the SEC on March 3, 2023, disclosing ownership and transactions involving the company's equity securities.
- The filing includes information on the reporting person's relationship to the company and purchases and sales of equity securities.
- The filing complies with the requirements of Section 12 of the '34 Act for publicly-traded companies to submit periodic statements of ownership.
- Directors, officers, and owners with a 10% stake in Seagen Inc.'s equity securities submit reports using Form 3 for initial filings and Form 4 for changes, with Form 5 serving as the annual statement of beneficial ownership.
- The SEC filing is a formal document or financial statement submitted to ensure transparency and accountability in corporate governance.
Statistics:
- The SIC code for Seagen Inc. is 2836, categorizing it under Biological Products, excluding Diagnostic Substances.
- The SEC file number for this filing is 0001203311-23-000022.
- The contact information for Seagen Inc. listed in the filing is 21823 30TH DRIVE SE, SUITE, BOTHELL WA 98021, 4255274000.
- The filer, Seagen Inc., is subject to Section 12 of the '34 Act for equity securities registered under the act.
Sources:
- NewsReporter-Staff News Editor at Life Science Weekly
- "News Reporting originating from Washington, D.C."
- NewsRx journalists
- Seagen Inc. SEC filing (Form 4) on March 3, 2023